使用 Z 型 V 2 O 5 /gC 3 N 4异质结作为可回收光催化剂,在室温惰性气氛中,在添加剂的作用下,建立了可见光引发的喹喔啉-2(1 H )-酮的 C-H 三氟甲基化反应-自由且温和的条件。多种三氟甲基化喹喔啉-2-(1 H )-酮衍生物以中等到高产率异质生成,表现出良好的官能团耐受性。值得注意的是,可回收的V 2 O 5 /gC 3 N 4催化剂可以重复使用五次,催化活性略有损失。
Visible-light induced C3-H trifluoromethylation of quinoxalin-2(1H)-ones with CF3SO2Cl under external photocatalyst-free conditions
作者:Xia Mi、Beibei Cui、Jingyu Zhang、Chao Pi、Xiuling Cui
DOI:10.1016/j.tetlet.2022.153693
日期:2022.3
light-induced C-H trifluoromethylation of quinoxalin-2(1H)-ones with CF3SO2Cl as CF3 radical source under photocatalyst-free conditions. The reaction proceeds smoothly through a radical process in the absence of photocatalyst and oxidant in moderate to good yields, thus offering an efficient and green method for the synthesis of 3-trifluoromethyl quinoxalin-2(1H)-ones.
本文报道了在无光催化剂条件下,以 CF 3 SO 2 Cl 作为 CF 3自由基源的 quinoxalin-2(1 H )-ones的可见光诱导 CH 三氟甲基化。该反应在没有光催化剂和氧化剂的情况下以中等至良好的收率通过自由基过程顺利进行,从而为合成3-三氟甲基喹喔啉-2( 1H )-酮提供了一种高效、绿色的方法。
Direct C−H Trifluoromethylation of Quinoxalin-2(1<i>H</i>
)-ones under Transition-Metal-Free Conditions
herein is a direct C−H trifluoromethylation of quinoxalin‐2(1H)‐ones with sodium trifluoromethanesulfinate. This protocol affords a series of 3‐trifluoromethylquinoxalin‐2(1H)‐one derivatives in moderate to excellent yields under transition‐metal‐freeconditions. The present methodology features utilization of the inexpensive trifluoromethyl source without transition‐metal‐catalysts, mild reaction conditions
An efficient approach using a photocatalytic strategy for C−Hperfluoroalkylation of quinoxalinonesunderaerobicoxidationcondition has been developed. Such transformation employs readily available sodium perfluoroalkanesulfinates as perfluoroalkylation reagents and demonstrates good functional group compatibility, affording corresponding products in moderate to good yields. Compared with previous
The present invention relates to compounds that are late sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I):
wherein R
1
, R
2
, R
3
, and R
4
are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.